BioPharmSignal logoBioPharmSignal

Biotech News

Orchard Therapeutics Announces Multiple Data Presentations and Receives 2025 New Treatment Award at the 21st Annual WORLDSymposium™

Orchard Therapeutics (ORTX)Orchard TherapeuticsCompany update

Featured data showcase the transformative potential of HSC gene therapy to enable cross-correction and restore enzymatic function in a variety of tissues and organs, including the CNS TOKYO, LONDON and BOSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Orchard Therapeutics, a Kyowa Kirin company, today

Related news

ORTXOrchard Therapeutics2025-05-13 11:01 EST

Orchard Therapeutics Announces New England Journal of Medicine Publication of Long-term Clinical Outcomes from its HSC Gene Therapy for MLD and Multiple Presentations at ASGCT 2025

ORTXOrchard Therapeutics2024-10-23 15:31 EST

Orchard Therapeutics Announces Multiple Data Presentations and Publications

View all latest news

Orchard Therapeutics

Orchard Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

ORTXOrchard Therapeutics2025-12-16 17:15 EST

Orchard Therapeutics Celebrates Addition of Metachromatic Leukodystrophy to the U.S. Recommended Uniform Screening Panel

ORTXOrchard Therapeutics2025-10-28 06:00 EST

Kyowa Kirin and Orchard Therapeutics Announce OTL-200 Granted Orphan Regenerative Medicine Product Designation for Early-onset MLD in Japan

ORTXOrchard Therapeutics2025-07-07 11:00 EST

Orchard Therapeutics Announces Last Patient Treated in Registrational Trial of OTL-203 for MPS-I Hurler Syndrome

ORTXOrchard Therapeutics2025-05-13 11:01 EST

Orchard Therapeutics Announces New England Journal of Medicine Publication of Long-term Clinical Outcomes from its HSC Gene Therapy for MLD and Multiple Presentations at ASGCT 2025

ORTXOrchard Therapeutics2025-02-12 12:01 EST

Orchard Therapeutics Appoints Robin Kenselaar to Chief Commercial Officer and Announces Multiple Business Updates Pertaining to its Approved HSC Gene Therapy for MLD

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biopharma
Location
United States